Rational Design of Highly Active and Selective Ligands for the α5β1 Integrin Receptor
Authors:
- 9 June 2008
- journal article
- research article
- Published by Wiley in ChemBioChem
- Vol. 9 (9) , 1397-1407
Abstract
The inhibition of integrin function is a major challenge in medicinal chemistry. Potent ligands are currently in different stages of clinical trials for the antiangiogenic therapy of cancer and age‐related macula degeneration (AMD). The subtype α5β1 has recently been drawn into the focus of research because of its genuine role in angiogenesis. In our previous work we could demonstrate that the lack of structural information about the receptor could be overcome by a homology model based on the X‐ray structure of the αvβ3 integrin subtype and the sequence similarities between both receptors. In this work, we describe the rational design and synthesis of high affinity α5β1 binders, and the optimisation of selectivity against αvβ3 by means of extensive SAR studies and docking experiments. A first series of compounds based on the tyrosine scaffold resulted in affinities in the low and even subnanomolar range and selectivities of 400‐fold against αvβ3. The insights about the structure–activity relationship gained from tyrosine‐based ligands could be successfully transferred to ligands that bear an aza‐glycine scaffold to yield α5β1 ligands with affinities of ∼1 nm and selectivities that exceed 104‐fold. The ligands have already been successfully employed as selective α5β1 ligands in biological research and might serve as lead structures for antiangiogenic cancer therapy.Keywords
This publication has 64 references indexed in Scilit:
- Targeting RGD Recognizing Integrins: Drug Development, Biomaterial Research, Tumor Imaging and TargetingCurrent Pharmaceutical Design, 2006
- Spatial and Temporal Sequence of Events in Cell Adhesion: From Molecular Recognition to Focal Adhesion AssemblyChemBioChem, 2004
- Role of angiogenesis in tumor growth and metastasisSeminars in Oncology, 2002
- IntegrinsCell, 2002
- Stereoisomeric Peptide Libraries and Peptidomimetics for Designing Selective Inhibitors of the αvβ3 Integrin for a New Cancer TherapyAngewandte Chemie International Edition, 1997
- Stereoisomere Peptid‐Bibliotheken und Peptidmimetika zum Design von selektiven Inhibitoren des αv β3‐Integrins für eine neuartige KrebstherapieAngewandte Chemie, 1997
- Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vesselsCell, 1994
- Arg‐Gly‐Asp constrained within cyclic pentapoptides Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1FEBS Letters, 1991
- Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actinCell, 1986
- Transplacental Carcinogenesis by StilbestrolNew England Journal of Medicine, 1971